AstraZeneca at the European Society for Medical Oncology (ESMO) 2017 Congress

At AstraZeneca we are committed to pushing the boundaries of oncology research. With patients at the core of everything we do, we continue to drive towards transforming the oncology therapy landscape. Our science-led approach continually evolves and we are pleased to be presenting our latest data on both pipeline and marketed products at Europe’s premier cancer meeting, the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain.

Follow us on Twitter at @AstraZeneca and join the ESMO conversation at #ESMO17.

Investors and analysts can join the AstraZeneca Investor Science Event at ESMO 2017 webcast.

A Renaissance in Lung Cancer Research at ESMO 2017

Patients are at the core of what we do, and we’re pleased to have many advocacy partners to help steer our focus in developing treatments that serve those with the greatest unmet need. Dr Matthew Peters, Chair of the Global Lung Cancer Coalition, discusses what progress in treatment means in lung cancer and how the advocacy community can work to advance care for patients.

Lung Cancer – Our Focus at ESMO 2017

Our ambition is to use pioneering science to develop therapies for patients with lung cancer across all stages of disease and lines of treatment. At ESMO, we are pleased to be presenting the latest on therapies that leverage diverse scientific platforms to attack cancer, with a focus on biomarker-guided therapies that target key genetic drivers and therapies that boost the power of the immune response.

Supporting Social Media Citizens at ESMO 2017

We’re building on our commitment to being a “better social media citizen” during ESMO 2017. Our Director of Corporate Social Media, Annie Sullivan, explains how we will support the exchange of ideas and amplify the conversation beyond Madrid’s convention centre. 

Lung Cancer is More Than One Disease

Our infographic explains more about different mechanisms that contribute to tumour development in lung cancer.

Advancing Treatment Selection for Patients With Hormone Receptor-Positive Advanced Breast Cancer

For patients with advanced or metastatic breast cancer, treatment options vary depending on tumour classification, previous treatment and whether there is a need for symptomatic therapy. John Boyer explains how identifying the right treatment for the right patient is a complex process, but the benefits for both quality of life and length of survival, may be immeasurable. 

Representing the Patient With Social Media at ESMO 2017

Social media will host a vibrant conversation at ESMO 2017, with patient groups working to ensure that the patients they support are well-represented online. Here our Global Director of Oncology Patient Group Relations, Martha Orzechowski, talks to Lydia Makaroff & Anna Rek of the European Cancer Patients Coalition discusses how they are preparing for #ESMO17.

Cracking the CODE: Collecting Data to Inform Treatment and Support Access to Treatment

Big data has the potential to unlock new ways of delivering cancer care but little is known about current cancer treatment use and its outcomes. Ashley Woolmore, Initiative Lead for CODE, QuintilesIMS, discusses the value that the Collaboration for Oncology Data in Europe project can bring to patients and healthcare systems by creating a new oncology data network.

Veeva ID: Z4-6491
Date of next review: August 2018